A Study to Evaluate the Efficacy and Safety of Radion™-Pdt in Patients With Oral Precancerous Lesion
A Prospective, Single-Arm, Open-Label, Phase II. Study to Evaluate the Efficacy and Safety of Photodynamic Therapy Using Radion™-Pdt in Patients With Oral Precancerous Lesion (Oral Verrucous Hyperplasia or Oral Erythroleukoplakia)
Sponsor: Pharma Power Biotec Co., Ltd.
This PHASE2 trial investigates Erythroleukoplakia of Mouth and Verrucous Hyperplasia of Oral Mucosa and is currently completed. Pharma Power Biotec Co., Ltd. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 2 earlier versions
-
Jun 2018 — Aug 2019 [monthly]
Enrolling By Invitation PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE2
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pharma Power Biotec Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .